Læknaneminn - 01.04.2020, Blaðsíða 48

33. Baloh RW. Clinical practice. Vestibular neuritis. N Engl J Med 2003;
348: 1027-32.
34. Strupp M, Zingler VC, Arbusow V, et al. Methylprednisolone,
valacyclovir, or the combination for vestibular neuritis. N Engl J Med
2004; 351: 354-61.
35. Lewis RF, Nicoucar K, Gong W, et al. Adaptation of vestibular tone
studied with electrical stimulation of semicircular canal afferents. J Assoc
Res Otolaryngol 2013; 14: 331-40.
36. Spiegel R, Rust H, Baumann T, et al. Treatment of dizziness: an
interdisciplinary update. Swiss Med Wkly 2017; 147: w14566.
37. Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment
of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane
Database Syst Rev 2011: Cd008607.
38. Moshtaghi O, Sahyouni R, Lin HW, et al. A Historical Recount:
Discovering Meniere’s Disease and Its Association With Migraine
Headaches. Otology & neurotology : official publication of the American
Otological Society, American Neurotology Society [and] European
Academy of Otology and Neurotology 2016; 37: 1199-203.
39. Gurkov R, Pyyko I, Zou J, et al. What is Meniere’s disease? A
contemporary re-evaluation of endolymphatic hydrops. J Neurol 2016;
263 Suppl 1: S71-81.
40. Wright T. Meniere’s disease. BMJ clinical evidence 2015; 2015: 0505.
41. Wu V, Sykes EA, Beyea MM, et al. Approach to Meniere disease
management. Canadian family physician Medecin de famille canadien
2019; 65: 463-7.
42. Goebel JA. 2015 Equilibrium Committee Amendment to the 1995
AAO-HNS Guidelines for the Definition of Meniere’s Disease.
Otolaryngology--head and neck surgery : official journal of American
Academy of Otolaryngology-Head and Neck Surgery 2016; 154: 403-4.
43. Magnan J, Ozgirgin ON, Trabalzini F, et al. European Position Statement
on Diagnosis, and Treatment of Meniere’s Disease. The journal of
international advanced otology 2018; 14: 317-21.
44. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo.
Cochrane Database Syst Rev 2016: Cd010696.
45. Thirlwall AS, Kundu S. Diuretics for Meniere’s disease or syndrome.
Cochrane Database Syst Rev 2006: Cd003599.
46. Park JJ-H, Chen Y-S, Westhofen M. Meniere’s disease and middle ear
pressure – vestibular function after transtympanic tube placement. Acta
Oto-Laryngologica 2009; 129: 1408-13.
47. Kanegaonkar RG, Najuko-Mafemera A, Hone R, et al. Menière’s disease
treated by grommet insertion. Ann R Coll Surg Engl 2019; 101: 602-5.
48. Pullens B, van Benthem PP. Intratympanic gentamicin for Meniere’s
disease or syndrome. Cochrane Database Syst Rev 2011: Cd008234.
49. Pullens B, Verschuur HP, van Benthem PP. Surgery for Meniere’s disease.
Cochrane Database Syst Rev 2013: Cd005395.
50. Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation
of efficacy. Otolaryngology--head and neck surgery : official journal of
American Academy of Otolaryngology-Head and Neck Surgery 2000;
122: 340-5.
51. Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic
criteria. Journal of vestibular research : equilibrium & orientation 2012;
22: 167-72.
52. Furman JM, Marcus DA, Balaban CD. Vestibular migraine: clinical
aspects and pathophysiology. The Lancet Neurology 2013; 12: 706-15.
53. Liu YF, Xu H. The Intimate Relationship between Vestibular Migraine
and Meniere Disease: A Review of Pathogenesis and Presentation. Behav
Neurol 2016; 2016: 3182735.
54. Colombo B, Teggi R. Vestibular migraine: who is the patient?
Neurological sciences : official journal of the Italian Neurological Society
and of the Italian Society of Clinical Neurophysiology 2017; 38: 107-10.
55. Polensek SH, Tusa RJ. Nystagmus during attacks of vestibular migraine:
an aid in diagnosis. Audiology & neuro-otology 2010; 15: 241-6.
56. Minor LB, Solomon D, Zinreich JS, et al. Sound- and/or pressure-
induced vertigo due to bone dehiscence of the superior semicircular canal.
Archives of otolaryngology--head & neck surgery 1998; 124: 249-58.
57. Chilvers G, McKay-Davies I. Recent advances in superior semicircular
canal dehiscence syndrome. The Journal of laryngology and otology 2015;
129: 217-25.
58. Mau C, Kamal N, Badeti S, et al. Superior semicircular canal dehiscence:
Diagnosis and management. Journal of clinical neuroscience : official
journal of the Neurosurgical Society of Australasia 2018; 48: 58-65.
59. Hirvonen TP, Carey JP, Liang CJ, et al. Superior canal dehiscence:
mechanisms of pressure sensitivity in a chinchilla model. Archives of
otolaryngology--head & neck surgery 2001; 127: 1331-6.
60. Gondivkar S, Parikh V, Parikh R. Herpes zoster oticus: A rare clinical
entity. Contemp Clin Dent 2010; 1: 127-9.
61. Brandt T, Strupp M, Dieterich M. Vestibular paroxysmia: a treatable
neurovascular cross-compression syndrome. J Neurol 2016; 263 Suppl 1:
S90-S6.
Leiðrétting Höfundum þykir miður að villandi framsetning er í Töflu II.
Skilgreiningar á sýringu og lýtingu. Í skilgreiningu á lýtingu kemur
fram að 7,45 > pH > 7,4 sem er ekki rétt og sama á við um sýringu þar
sem segir að 7,4 > pH > 7,35. Þessi skilgreining á sýringu og lýtingu
felur í sér viðeigandi aðlögunarviðbragð sem heldur sýrustiginu
innan marka. Eftir á að hyggja er þessi framsetning líkleg til að valda
ruglingi.
Leiðrétt útgáfa af töflu II. er hér fyrir neðan.
Tafla II. Skilgreiningar á sýringu og lýtingu.
pH >7,45 og lækkun á PCO2 eða hækkun
á [HCO3
-]
Lýting
pH <7,35 og lækkun á [HCO3
-] eða
hækkun á PCO2
Sýring
Hér er komið á framfæri
leiðréttingu við greinina
“Klínísk nálgun sýru- og
basaraskana: Efnaskiptasýring
og efnaskiptalýting” sem birtist
í Læknanemanum 2019;70:30-
39.
Höfundar: Stella Rún
Guðmundsdóttir og Runólfur
Pálsson.